Beam Therapeutics EV / EBITDA
Was ist das EV / EBITDA von Beam Therapeutics?
EV / EBITDA von Beam Therapeutics Inc. ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Beam Therapeutics
Was macht Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Unternehmen mit ev / ebitda ähnlich Beam Therapeutics
- Castile Resources hat EV / EBITDA von N/A
- Greenhill & Co Inc hat EV / EBITDA von N/A
- Cool Link () hat EV / EBITDA von N/A
- Syntonic hat EV / EBITDA von N/A
- Merida Minerals Inc hat EV / EBITDA von N/A
- Golden Meditech hat EV / EBITDA von N/A
- Beam Therapeutics hat EV / EBITDA von N/A
- Hummingbird Resources Plc hat EV / EBITDA von N/A
- Tern Plc hat EV / EBITDA von N/A
- Magnis Resources hat EV / EBITDA von N/A
- Fastly Inc hat EV / EBITDA von N/A
- Soliton hat EV / EBITDA von N/A
- WeTrade hat EV / EBITDA von N/A